| Literature DB >> 25880912 |
Kazuya Okushin1, Yu Takahashi2, Nobutake Yamamichi3, Takeshi Shimamoto4, Kenichiro Enooku5, Hidetaka Fujinaga6, Takeya Tsutsumi7, Yoshizumi Shintani8, Yoshiki Sakaguchi9, Satoshi Ono10, Shinya Kodashima11, Mitsuhiro Fujishiro12, Kyoji Moriya13, Hiroshi Yotsuyanagi14, Toru Mitsushima15, Kazuhiko Koike16.
Abstract
BACKGROUND: Fatty liver disease (FLD) including non-alcoholic fatty liver disease (NAFLD), a rapidly emerging and widely recognized liver disease today, is regarded as a hepatic manifestation of metabolic syndrome. Helicobacter pylori, one of the most common pathogens worldwide, has been reported to be associated with metabolic syndrome, but whether there is a direct association with FLD is as of yet unclear. The aim of this study was to clarify the association of FLD and NAFLD with causative background factors including Helicobacter pylori infection.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25880912 PMCID: PMC4349671 DOI: 10.1186/s12876-015-0247-9
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Figure 1Of the 20,773 asymptomatic adults attended, 13,737 subjects were mainly analyzed in our present study. The subcategory of 5,289 subjects who were not affected by alcohol was also analyzed. Each figure presenting excluded patients was overlapping at the same box.
Characteristics of the 13,737 subjects (6,318 females and 7,419 males) focusing on the presence of fatty liver disease (FLD) and its association with 19 continuous variables
| ᅟ | Female | Male | ||||
|---|---|---|---|---|---|---|
| Variables | FLD(N = 1456) | non-FLD(N = 4862) | FLD(N = 3498) | non-FLD(N = 3921) | ||
| Age (years old) | 50.3 ± 7.9 | 46.9 ± 8.6 | <0.0001* | 48.7 ± 8.4 | 48.1 ± 9.5 | 0.0012* |
| Height (cm) | 157.3 ± 5.6 | 158.2 ± 5.4 | <0.0001* | 170.8 ± 5.8 | 171.0 ± 5.9 | 0.0717 |
| Weight (kg) | 61.8 ± 9.6 | 51.4 ± 6.2 | <0.0001* | 72.8 ± 9.7 | 64.6 ± 7.8 | <0.0001* |
| BMI (kg/m2) | 25.0 ± 3.6 | 20.5 ± 2.2 | <0.0001* | 24.9 ± 2.8 | 22.1 ± 2.2 | <0.0001* |
| AST (IU/l) | 21.2 ± 8.9 | 19.0 ± 5.4 | <0.0001* | 24.6 ± 10.0 | 21.3 ± 17.1 | <0.0001* |
| ALT (IU/l) | 23.0 ± 16.7 | 16.0 ± 7.6 | <0.0001* | 33.5 ± 22.6 | 21.6 ± 15.9 | <0.0001* |
| GGT (IU/l) | 28.3 ± 27.8 | 19.3 ± 17.3 | <0.0001* | 55.6 ± 58.2 | 38.8 ± 38.3 | <0.0001* |
| T-Bil (mg/dl) | 0.71 ± 0.27 | 0.76 ± 0.27 | <0.0001* | 0.87 ± 0.35 | 0.90 ± 0.37 | 0.0045* |
| ALB (g/dl) | 4.26 ± 0.21 | 4.25 ± 0.21 | 0.1028 | 4.40 ± 0.22 | 4.36 ± 0.22 | <0.0001* |
| PLT (104/μl) | 26.1 ± 5.9 | 23.7 ± 5.4 | <0.0001* | 23.9 ± 4.9 | 22.9 ± 4.7 | <0.0001* |
| TC (mg/dl) | 214.0 ± 34.1 | 198.8 ± 33.0 | <0.0001* | 207.7 ± 32.5 | 195.4 ± 30.5 | <0.0001* |
| HDL-C (mg/dl) | 64.7 ± 14.2 | 75.8 ± 15.4 | <0.0001* | 54.1 ± 12.7 | 63.8 ± 15.2 | <0.0001* |
| LDL-C (mg/dl) | 135.0 ± 32.3 | 114.2 ± 29.9 | <0.0001* | 134.8 ± 30.2 | 119.4 ± 28.9 | <0.0001* |
| TG (mg/dl) | 107.2 ± 80.8 | 68.2 ± 32.0 | <0.0001* | 151.3 ± 97.6 | 98.7 ± 62.6 | <0.0001* |
| HbA1c (%) | 5.52 ± 0.56 | 5.30 ± 0.33 | <0.0001* | 5.50 ± 0.62 | 5.29 ± 0.37 | <0.0001* |
| FBS (mg/dl) | 94.9 ± 15.2 | 88.3 ± 8.5 | <0.0001* | 100.1 ± 16.4 | 94.1 ± 10.0 | <0.0001* |
| SBP (mmHg) | 118.8 ± 16.5 | 107.7 ± 14.5 | <0.0001* | 121.4 ± 15.0 | 115.4 ± 14.7 | <0.0001* |
| DBP (mmHg) | 73.9 ± 10.5 | 67.2 ± 9.6 | <0.0001* | 77.0 ± 10.1 | 73.0 ± 9.8 | <0.0001* |
| Waist (cm) | 87.2 ± 8.6 | 75.7 ± 6.5 | <0.0001* | 87.4 ± 7.1 | 79.8 ± 6.4 | <0.0001* |
FLD: fatty liver disease. Data show mean ± SD (standard deviation) of each variable. By applying the Welch’s t test or Wilcoxon analysis, p values were calculated. The level of significance was set below 0.01 (*).
Characteristics of the 13,737 subjects (6,318 females and 7,419 males) focusing on the presence of fatty liver disease (FLD) and its association with four categorized variables
| ᅟ | Female | Male | ||||
|---|---|---|---|---|---|---|
| Variables | FLD(N = 1456) | non-FLD(N = 4862) | FLD(N = 3498) | non-FLD(N = 3921) | ||
| MS | ᅟ | ᅟ | <0.0001* | ᅟ | ᅟ | <0.0001* |
| Non-MS | 1391 (22.3 %) | 4860 (77.6 %) | ᅟ | 2945 (43.5 %) | 3832 (56.5 %) | ᅟ |
| MS | 65 (97.0 %) | 2 (3.0 %) | 553 (86.1 %) | 89 (13.9 %) | ᅟ | |
| Alcohol | ᅟ | ᅟ | <0.0001* | ᅟ | ᅟ | <0.0001* |
| Non-drinker | 884 (25.3 %) | 2604 (74.7 %) | 951 (50.8 %) | 923 (49.3 %) | ᅟ | |
| Occasional-drinking | 368 (20.2 %) | 1456 (79.8 %) | ᅟ | 1114 (49.9 %) | 1120 (50.1 %) | ᅟ |
| Daily-drinker | 204 (20.3 %) | 802 (79.7 %) | ᅟ | 1433 (43.3 %) | 1878 (56.7 %) | ᅟ |
| Smoking | ᅟ | ᅟ | 0.0467 | ᅟ | ᅟ | 0.0045* |
| Current-smoker | 123 (27.8 %) | 319 (72.2 %) | 1116 (49.3 %) | 1147 (50.7 %) | ||
| Former-smoker | 174 (23.2 %) | 577 (76.8 %) | ᅟ | 1317 (47.6 %) | 1450 (52.4 %) | ᅟ |
| Never-smoker | 1159 (22.6 %) | 3966 (77.4 %) | ᅟ | 1065 (44.6 %) | 1324 (55.4 %) | ᅟ |
| ᅟ | ᅟ | <0.0001* | ᅟ | ᅟ | 0.6446 | |
| Negative | 1003 (21.5 %) | 3665 (78.5 %) | ᅟ | 2474 (47.0 %) | 2793 (53.0 %) | ᅟ |
| Positive | 453 (27.5 %) | 1197 (72.6 %) | ᅟ | 1024 (47.6 %) | 1128 (52.4 %) | ᅟ |
FLD: fatty liver disease, MS: metabolic syndrome, Ab: antibody. By applying the Fisher’s exact test, p values were calculated. The level of significance was set below 0.01 (*).
Multivariate analyses evaluating association between the presence of fatty liver disease (FLD) and 9 selected variables among the 13,737 subjects (6,318 females and 7,419 males).
| ᅟ | Female | Male | ||||
|---|---|---|---|---|---|---|
| Variables | Standardized coefficient | Standard error | Standardized coefficient | Standard error | ||
| BMI | 143.5 | 4.8 | <0.0001* | 102.5 | 3.7 | <0.0001* |
| ALT | 25.8 | 5.1 | <0.0001* | 75.7 | 13.1 | <0.0001* |
| Age | 34.3 | 3.5 | <0.0001* | 17.2 | 2.8 | <0.0001* |
| PLT | 17.8 | 3.1 | <0.0001* | 15.2 | 2.6 | <0.0001* |
| Alcohol | ᅟ | ᅟ | ᅟ | ᅟ | ᅟ | ᅟ |
| Occasional-drinker | −8.1 | 3.7 | 0.0270 | −5.9 | 2.8 | 0.0371 |
| Daily-drinker | 8.5 | 3.7 | 0.0209 | −8.4 | 2.9 | 0.0040* |
| MS | ᅟ | ᅟ | ᅟ | ᅟ | ᅟ | ᅟ |
| Positive | 10.2 | 5.9 | 0.0804 | 16.4 | 3.2 | <0.0001* |
| GGT | 5.3 | 3.1 | 0.0919 | 4.0 | 4.1 | 0.3399 |
| T-Bil | −3.1 | 3.3 | 0.3386 | 1.4 | 2.4 | 0.5555 |
|
| ᅟ | ᅟ | ᅟ | ᅟ | ᅟ | ᅟ |
| Positive | 1.0 | 3.1 | 0.7558 | −2.8 | 2.5 | 0.2642 |
MS: metabolic syndrome, C.I.: confidence interval, Ab: antibody, Using the logistic regression analysis, p values were calculated. The level of significance was set below 0.01 (*).
Characteristics of the alcohol-free 5,289 subjects (3,473 females and 1,816 males) focusing on the presence of fatty liver (NAFLD) and its association with 19 continuous variables
| ᅟ | Female | Male | ||||
|---|---|---|---|---|---|---|
| Variables | NAFLD(N = 881) | non-NAFLD(N = 2592) | NAFLD(N = 921) | non-NAFLD(N = 895) | ||
| Age (years old) | 50.8 ± 8.1 | 47.6 ± 8.9 | <0.0001* | 47.6 ± 8.6 | 47.4 ± 10.1 | 0.5126 |
| Height (cm) | 156.9 ± 5.4 | 157.8 ± 5.5 | <0.0001* | 170.7 ± 5.8 | 170.9 ± 6.0 | 0.4956 |
| Weight (kg) | 61.8 ± 9.8 | 51.2 ± 6.3 | <0.0001* | 72.8 ± 10.0 | 63.8 ± 8.0 | <0.0001* |
| BMI (kg/m2) | 25.1 ± 3.7 | 20.5 ± 2.3 | <0.0001* | 25.0 ± 3.0 | 21.8 ± 2.3 | <0.0001* |
| AST (IU/l) | 21.4 ± 9.2 | 19.0 ± 5.4 | <0.0001* | 23.8 ± 10.6 | 20.0 ± 5.3 | <0.0001* |
| ALT (IU/l) | 23.5 ± 17.7 | 16.2 ± 7.8 | <0.0001* | 35.1 ± 30.7 | 21.3 ± 9.4 | <0.0001* |
| GGT (IU/l) | 26.4 ± 24.6 | 18.2 ± 14.8 | <0.0001* | 40.5 ± 41.0 | 26.6 ± 22.4 | <0.0001* |
| T-Bil (mg/dl) | 0.71 ± 0.26 | 0.74 ± 0.26 | <0.0004* | 0.85 ± 0.36 | 0.86 ± 0.37 | 0.5524 |
| ALB (g/dl) | 4.26 ± 0.22 | 4.24 ± 0.21 | 0.0148 | 4.41 ± 0.23 | 4.35 ± 0.22 | <0.0001* |
| PLT (104/μl) | 26.1 ± 6.0 | 23.7 ± 5.6 | <0.0001* | 24.7 ± 5.1 | 22.9 ± 4.9 | <0.0001* |
| TC (mg/dl) | 213.2 ± 33.4 | 201.2 ± 33.6 | <0.0001* | 207.4 ± 32.9 | 192.6 ± 29.9 | <0.0001* |
| HDL-C (mg/dl) | 62.9 ± 14.0 | 74.1 ± 15.0 | <0.0001* | 50.5 ± 10.7 | 59.5 ± 13.8 | <0.0001* |
| LDL-C (mg/dl) | 136.0 ± 31.8 | 118.2 ± 30.3 | <0.0001* | 138.6 ± 29.5 | 121.3 ± 27.8 | <0.0001* |
| TG (mg/dl) | 107.8 ± 71.0 | 69.1 ± 31.2 | <0.0001* | 144.1 ± 92.0 | 91.6 ± 47.7 | <0.0001* |
| HbA1c (%) | 5.55 ± 0.54 | 5.34 ± 0.35 | <0.0001* | 5.51 ± 0.63 | 5.31 ± 0.40 | <0.0001* |
| FBS (mg/dl) | 94.5 ± 14.7 | 88.1 ± 9.1 | <0.0001* | 98.4 ± 17.0 | 92.2 ± 8.5 | <0.0001* |
| SBP (mmHg) | 119.4 ± 16.8 | 107.7 ± 14.4 | <0.0001* | 118.6 ± 14.5 | 111.2 ± 13.3 | <0.0001* |
| DBP (mmHg) | 74.2 ± 10.6 | 66.9 ± 9.5 | <0.0001* | 74.9 ± 9.4 | 70.0 ± 8.8 | <0.0001* |
| Waist (cm) | 87.3 ± 8.7 | 75.7 ± 6.5 | <0.0001* | 87.3 ± 7.5 | 78.6 ± 6.6 | <0.0001* |
NAFLD: non-alcoholic fatty liver disease. Data show mean ± SD (standard deviation) of each variable. By applying the Welch’s t test or Wilcoxon analysis, p values were calculated. The level of significance was set below 0.01 (*).
Characteristics of the alcohol-free 5,289 subjects (3,473 females and 1,816 males) focusing on the presence of fatty liver (NAFLD) and its association with three categorized variables
| ᅟ | Female | Male | ||||
|---|---|---|---|---|---|---|
| Variables | NAFLD(N = 881) | non-NAFLD(N = 2592) | NAFLD(N = 921) | non-NAFLD(N = 895) | ||
| MS | ᅟ | ᅟ | <0.0001* | ᅟ | ᅟ | <0.0001* |
| Non-MS | 838 (24.5 %) | 2590 (75.6 %) | 793 (47.2 %) | 886 (52.8 %) | ᅟ | |
| MS | 43 (95.6 %) | 2 (4.4 %) | ᅟ | 128 (93.4 %) | 9 (6.6 %) | ᅟ |
| Smoking | ᅟ | ᅟ | 0.3913 | ᅟ | ᅟ | 0.0033* |
| Current-smoker | 54 (29.4 %) | 130 (70.7 %) | 289 (54.4 %) | 242 (45.6 %) | ᅟ | |
| Former-smoker | 71 (24.0 %) | 225 (76.0 %) | ᅟ | 284 (53.7 %) | 245 (46.3 %) | ᅟ |
| Never-smoker | 756 (25.3 %) | 2237 (74.7 %) | ᅟ | 348 (46.0 %) | 408 (54.0 %) | ᅟ |
| ᅟ | ᅟ | 0.0145 | ᅟ | ᅟ | 0.8742 | |
| Negative | 610 (24.2 %) | 1907 (75.8 %) | ᅟ | 669 (50.6 %) | 654 (49.4 %) | ᅟ |
| Positive | 271 (28.4 %) | 685 (71.7 %) | ᅟ | 252 (51.1 %) | 241 (48.9 %) | ᅟ |
NAFLD: non-alcoholic fatty liver disease, MS: metabolic syndrome, Ab: antibody. By applying the Fisher’s exact test, p values were calculated. The level of significance was set below 0.01 (*).
Multivariate analysis evaluating association between NAFLD and 7 selected variables among the non-drinking 5,289 subjects (3,473 females and 1,816 males)
| ᅟ | Female | Male | ||||
|---|---|---|---|---|---|---|
| Variables | Standardized Coefficient | Standard error | Standardized Coefficient | Standard error | ||
| BMI | 113.3 | 4.9 | <0.0001* | 55.3 | 3.7 | <0.0001* |
| ALT | 21.6 | 6.1 | 0.0004* | 53.8 | 6.5 | <0.0001* |
| Age | 25.0 | 3.5 | <0.0001* | 3.7 | 2.6 | 0.1607 |
| PLT | 13.8 | 3.0 | <0.0001* | 11.8 | 2.5 | <0.0001* |
| MS | ᅟ | ᅟ | ᅟ | ᅟ | ᅟ | ᅟ |
| Positive | 5.9 | 5.0 | 0.2354 | 11.6 | 4.5 | 0.0092* |
| GGT | 2.3 | 3.4 | 0.4975 | 0.24 | 3.9 | 0.9508 |
|
| ᅟ | ᅟ | ᅟ | ᅟ | ᅟ | ᅟ |
| Positive | −1.2 | 3.1 | 0.7017 | −1.8 | 2.6 | 0.4764 |
MS: metabolic syndrome, Ab: antibody, C.I.: confidence interval. Using the logistic regression analysis, p values were calculated. The level of significance was set below 0.01 (*).